AbbVie extends Gedeon Richter alliance that gave it Vraylar
pharmaphorum
MARCH 11, 2022
Vraylar, sold in some markets as Reagila, was first approved in 2015 for schizophrenia and bipolar disorder, with its label extended in 2017 to include maintenance treatment of schizophrenia and again in 2019 for bipolar depression.
Let's personalize your content